アレルギー免疫療法市場：アレルゲンタイプ別、年齢層別、免疫療法タイプ別、流通チャネル別、地域別、2024年～2031年

アレルギー免疫療法の市場評価-2024年～2031年

アレルギー免疫療法の市場規模は2023年に20億8,000万米ドルと評価され、2031年までに38億7,000万米ドルの成長が予測され、予測期間中のCAGRは8.10％を示します。アレルギー免疫療法市場は、アレルギー性鼻炎、喘息、食物アレルギーなどのアレルギー疾患の頻度増加により拡大しています。効果的で長期的な治療法を求める人が増えるにつれ、標準的な薬剤よりも免疫療法を好む傾向が明確になってきています。これは、抗ヒスタミン薬や副腎皮質ステロイド薬を常時使用することなく症状を緩和したい人々には特に当てはまります。

さらに、アレルゲン特異的免疫療法製品や舌下錠や注射などの投与方法の進歩により、患者のアクセスやアドヒアランスが向上しています。免疫療法の利点に対する認識の高まりと医療専門家の推奨が、市場拡大の原動力となっています。個別化医療が重視される中、アレルギー免疫療法産業は今後数年間で大きく成長すると予想されます。

アレルギー免疫療法市場定義/概要

アレルギー免疫療法は、アレルゲンに対する感受性を低下させ、アレルギー症状を長期的に緩和することを目的とした治療法です。特定のアレルゲンを皮下注射（アレルゲン免疫療法）または舌下錠／点滴で徐々に増量していく。このメカニズムにより、免疫系がアレルゲンに対する耐性を獲得し、アレルギー反応の重症度が軽減されます。

特定のアレルゲンに対する免疫系の感受性を徐々に低下させることで、アレルギー疾患を治療します。注射（皮下免疫療法）や舌下錠によって、アレルゲンを制御された量だけイントロダクションします。この方法は、時間とともにアレルギー反応の重症度を低下させ、治療終了後も長期にわたって症状を緩和することができます。アレルギー免疫療法は、アレルギー性鼻炎、喘息、特定の食物アレルギーなどの疾患に対して有益であり、患者の生活の質を高め、薬剤の使用量を減少させる。

アレルギー免疫療法の将来は、遺伝子やバイオマーカーのデータを利用して特定の患者に薬を適応させる個別化治療技術が中心になると思われます。マイクロニードルやウェアラブルデバイスのような革新的ドラッグデリバリーシステムは、患者のコンプライアンスと快適性を向上させると期待されています。さらに、新たなアレルゲン源や併用薬に関する研究により、治療の選択肢が広がると思われます。

ヘルスケア専門家および患者の意識の高まりは、アレルギー免疫療法市場の成長にどのような影響を与えているか？

ヘルスケア専門家や患者の間での意識の高まりが、アレルギー免疫療法市場の成長を加速させています。より多くの医療従事者が、従来のアレルギー治療薬よりも免疫療法の方が長期的なメリットがあることを認識し、実行可能なアレルギー治療の選択肢として免疫療法を推進するようになっています。免疫療法の有効性と安全性に関する教育の向上に後押しされたこのような臨床実践の変化は、皮下免疫療法（SCIT）や舌下免疫療法（SLIT）のような治療法の受け入れ拡大につながり、市場の成長に寄与しています。

患者の観点からは、アレルギー免疫療法が一時的な症状緩和だけでなく、長期的な快適さを提供する能力に対する理解が深まり、これらの療法に対する需要が増加しています。患者は自分の選択肢をよりよく理解するようになり、個別化された長期的なアレルギー治療を選択する可能性が高まっています。このような需要の高まりとヘルスケア専門家による推薦が相まって、免疫療法の採用が進み、市場全体が拡大しています。

高い治療費はアレルギー免疫療法市場の抑制要因か？

治療費の高さは、アレルギー免疫療法市場において患者の治療へのアクセスを制限する大きな障壁となっています。アレルギー免疫療法、特に皮下免疫療法（SCIT）は数年にわたり数回の治療が必要であり、患者にとっては高額な治療費となります。多くの地域では、このような治療に対する保険適用は限られているか、あるいは適用されないことがあり、患者は現金で支払う必要があります。この治療法は慢性的なアレルギーの問題を長期的に緩和するものであるが、多くの人はその費用の高さに二の足を踏んでいます。

さらに、免疫療法には高額な初期費用と経常費用がかかるため、特に低所得地域やヘルスケア資源が不十分な国では、その利用が制限されています。大規模な免疫療法プログラムのためにリソースを割くことは、財政に余裕のないヘルスケアシステムにとっては現実的でない可能性があり、市場の拡大はさらに制限されます。その結果、アレルギーの罹患率が増加し、免疫療法の有効性が確立されているにもかかわらず、これらの治療法の普及にはコストが大きな障壁となっています。

目次

第1章 世界のアレルギー免疫療法市場：イントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次インタビュー
• データソース一覧

第4章 アレルギー免疫療法の世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 アレルギー免疫療法の世界市場：アレルゲンタイプ別

• 概要
• 季節性アレルゲン
• 通年性アレルゲン

第6章 アレルギー免疫療法の世界市場：年齢層別

• 概要
• 小児
• 成人

第7章 アレルギー免疫療法の世界市場：免疫療法タイプ別

• 概要
• 皮下免疫療法（SCIT）
• 舌下免疫療法（SLIT）

第8章 アレルギー免疫療法の世界市場：流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第9章 アレルギー免疫療法の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第10章 世界のアレルギー免疫療法市場：競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第11章 企業プロファイル

• ALK-Abello A/S
• Stallergenes Greer plc
• Allergy Therapeutics plc
• Aimmune Therapeutics, Inc.
• DBV Technologies SA
• HAL Allergy Group
• Biomay AG
• Circassia Pharmaceuticals plc
• Immunomic Therapeutics, Inc.
• Anergis

第12章 主な発展

• 製品の上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第13章 付録

• 関連調査

Allergy Immunotherapy Market Valuation - 2024-2031

Allergy Immunotherapy Market size was valued at USD 2.08 Billion in 2023 and is projected to grow USD 3.87 Billion by 2031, exhibiting a CAGR of 8.10% during the forecast period. The Allergy Immunotherapy Market is expanding due to the increasing frequency of allergic illnesses such as allergic rhinitis, asthma, and food allergies. As more people seek effective, long-term treatment alternatives, the preference for immunotherapy over standard drugs is becoming clear. This is especially true for people who want to relieve their symptoms without having to use antihistamines or corticosteroids all the time.

Furthermore, advances in allergen-specific immunotherapy products and administration modalities such as sublingual tablets and injections, are improving patient access and adherence. Increasing awareness of immunotherapy's benefits combined with recommendations from healthcare experts is driving market expansion. With an emphasis on personalized medication, the allergy immunotherapy industry is expected to grow significantly in the coming years.

Allergy Immunotherapy Market: Definition/ Overview

Allergy immunotherapy is a treatment that aims to lower sensitivity to allergens resulting in long-term relief from allergy symptoms. It entails gradually administering increasing doses of certain allergens, either via subcutaneous injections (allergen immunotherapy) or sublingual tablets/drops. This mechanism helps the immune system develop tolerance to allergens reducing the severity of allergic reactions.

It is used to treat allergy diseases by progressively reducing the immune system's sensitivity to specific allergens. It entails the introduction of allergens in controlled dosages by injections (subcutaneous immunotherapy) or sublingual pills. This approach reduces the severity of allergic reactions over time and can provide long-term relief, even after therapy is completed. Allergy immunotherapy is beneficial for illnesses such as allergic rhinitis, asthma, and specific food allergies enhancing patients' quality of life and lowering drug use.

The future of allergy immunotherapy will center on personalized treatment techniques that use genetic and biomarker data to adapt medicines to specific patients. Innovative drug delivery systems, such as microneedles and wearable devices are expected to improve patient compliance and comfort. Furthermore, studies on new allergen sources and combination medicines will expand therapy choices.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How has the Rising Awareness among Healthcare Professionals and Patients Impacted the Growth of the Allergy Immunotherapy Market?

Rising awareness among healthcare professionals and patients has accelerated the growth of the Allergy Immunotherapy Market. As more healthcare practitioners recognize the long-term benefits of immunotherapy over traditional allergy medications, they are more likely to promote it as a viable allergy management option. This shift in clinical practice, fuelled by improved education on the efficacy and safety of immunotherapy has resulted in increased acceptance of therapies such as Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT), hence contributing to market growth.

From the patient's perspective, a rising understanding of allergy immunotherapy's ability to provide long-term comfort, rather than just temporary symptom relief has resulted in increased demand for these therapies. As patients become more aware of their alternatives, they are more likely to choose personalized, long-term allergy treatments. This rising demand combined with professional endorsements from healthcare practitioners has pushed the adoption of immunotherapy propelling total market expansion.

How Does the High Cost of Treatment Act as a Restraint in the Allergy Immunotherapy Market?

The high cost of treatment is a significant barrier in the Allergy Immunotherapy Market limiting patient access to care. Allergy immunotherapy, particularly Subcutaneous Immunotherapy (SCIT) needs several sessions over several years which can be costly for patients. In many areas, insurance coverage for such therapies may be limited or absent requiring patients to pay out of cash. Even though the therapy provides long-term relief for chronic allergy problems, many people are put off by the cost.

Furthermore, the high initial and recurring costs associated with immunotherapy limit its accessibility, particularly in low-income regions or nations with inadequate healthcare resources. Allocating resources for extensive immunotherapy programs may be impractical for healthcare systems with limited finances, further restricting market expansion. As a result, despite the increasing incidence of allergies and the established efficacy of immunotherapy, cost remains a significant barrier to the wider use of these treatments.

Category-Wise Acumens

How Does the Method of Allergen Exposure in SCIT Contribute to the Long-Term Efficacy of Treatment for Allergic Diseases?

Subcutaneous Immunotherapy (SCIT) dominates the Allergy Immunotherapy Market due to its long-standing efficacy and comprehensive strategy. SCIT includes injecting allergen extracts directly under the skin allowing for controlled exposure and eventual desensitization of the immune system to specific allergens. This approach has been widely researched and shown helpful for a variety of allergens, notably pollen, dust mites, and animal dander making it a popular choice among both patients and healthcare providers looking for long-term relief.

Furthermore, SCIT provides a well-defined treatment regimen with established protocols resulting in predictable dose and response. The inclusion of multiple allergens in SCIT formulations allows for more personalized therapy options for patients which improves compliance and satisfaction. While sublingual immunotherapy (SLIT) is gaining popularity due to its simplicity of administration, SCIT remains dominant due to its proven track record, strong clinical data, and allergists' preference for its comprehensive approach to addressing allergic diseases.

How Does the Preparation of Personalized Immunotherapy Regimens in Hospital Pharmacies Affect Patient Adherence to Treatment Plans?

Hospital pharmacies dominate the allergy immunotherapy industry because they have access to a wide choice of specialized drugs and treatment alternatives. These pharmacies are ready to prepare and distribute personalized immunotherapy regimens such as allergy injections and sublingual pills, based on patient needs. The presence of allergists and immunologists in hospital settings promotes teamwork, resulting in better patient care and monitoring throughout the therapy process. This integrated strategy guarantees that patients receive timely and effective medicines which leads to better outcomes.

Furthermore, hospital pharmacies benefit from established partnerships with pharmaceutical producers allowing them to obtain the most recent immunotherapy medicines and updates on treatment methods. As hospitals implement multidisciplinary care models, coordination among chemists, healthcare professionals, and patients improves. This comprehensive strategy not only improves patient adherence to medication but also creates a supportive atmosphere for continued education and follow-up reinforcing hospital pharmacies' role in the Allergy Immunotherapy Market.

Country/Region-wise Acumens

How do Reimbursement Policies Influence Patient Access to Allergy Immunotherapy in the North American Region?

North America dominates the Allergy Immunotherapy Market, owing to the increasing prevalence of allergic illnesses like allergic rhinitis and asthma which drives demand for better treatment alternatives. The region benefits from excellent healthcare facilities, extensive research programs, and a thriving pharmaceutical sector. Major corporations are significantly investing in novel medicines such as subcutaneous and sublingual immunotherapy, to meet the rising patient population. Furthermore, as healthcare practitioners and patients become more aware of allergic disorders, acceptance and usage of immunotherapy treatments have increased.

Furthermore, supporting regulatory frameworks and favorable reimbursement policies in the United States promote market expansion. The Food and Drug Administration (FDA) has approved several immunotherapy medicines, increasing their market penetration. North American healthcare systems prioritize personalized medicine and patient-centered approaches which encourages the use of allergy immunotherapy. As a result, the region is well-positioned to sustain its market leadership opening the path for ongoing breakthroughs in treatment techniques.

How are Changing Lifestyles and Urbanization Impacting the Prevalence of Asthma and Allergic Rhinitis in the Asia-Pacific Region?

Asia Pacific is the fastest-growing region in the Allergy Immunotherapy Market owing to rising allergy incidence, increased healthcare awareness, and considerable investment in R&D. Urbanisation and changing lifestyles have contributed to an increase in allergy disorders such as asthma and allergic rhinitis creating a larger demand for effective treatments. As more people become aware of the benefits of immunotherapy, healthcare providers are more likely to recommend it resulting in increased market growth.

Furthermore, supportive government initiatives and partnerships with pharmaceutical companies improve access to allergy treatments and advances. The region's increasing middle class is pushing up healthcare spending allowing for the adoption of modern therapeutic choices. Furthermore, the expansion of healthcare infrastructure and the growing number of allergists and immunologists in countries such as China and India are key drivers of market growth. Overall, the combination of increased allergies and greater healthcare access has positioned Asia Pacific as a market leader in allergy immunotherapy.

Competitive Landscape

The Allergy Immunotherapy Market is a dynamic and competitive space characterized by diverse players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations focus on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the Allergy Immunotherapy Market include:

ALK-Abello A/S, Stallergenes Greer plc, Allergy Therapeutics plc, Merck & Co., Inc. (known as MSD outside of the United States and Canada), Aimmune Therapeutics, Inc., DBV Technologies SA, HAL Allergy Group, Biomay AG, Circassia Pharmaceuticals plc, Immunomic Therapeutics, Inc., Anergis, ASIT Biotech, and Adamis Pharmaceuticals Corporation.

Latest Developments

In January 2024, Inimmune Corporation (Inimmune) and Intrommune Therapeutics, Inc. (Intrommune), two clinical-stage immunotherapeutic companies, announced a collaboration to develop a novel oral mucosal allergy immunotherapy for treating peanut allergy.

In October 2023, ALK reported the successful completion of Itulatek's phase 3 trial for treating allergy rhinoconjunctivitis caused by tree pollen.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ALLERGY IMMUNOTHERAPY MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL ALLERGY IMMUNOTHERAPY MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY ALLERGEN TYPE

• 5.1 Overview
• 5.2 Seasonal Allergens
• 5.3 Perennial Allergens

6 GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY AGE GROUP

• 6.1 Overview
• 6.2 Children
• 6.3 Adults

7 GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY TYPE OF IMMUNOTHERAPY

• 7.1 Overview
• 7.2 Subcutaneous Immunotherapy (SCIT)
• 7.3 Sublingual Immunotherapy (SLIT)

8 GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL

• 8.1 Hospital Pharmacies
• 8.2 Retail Pharmacies
• 8.3 Online Pharmacies

9 GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East & Africa

10 GLOBAL ALLERGY IMMUNOTHERAPY MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Ranking
• 10.3 Key Development Strategies

11 COMPANY PROFILES

• 11.1 ALK-Abello A/S
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Stallergenes Greer plc
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Allergy Therapeutics plc
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Aimmune Therapeutics, Inc.
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 DBV Technologies SA
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 HAL Allergy Group
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 Biomay AG
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Circassia Pharmaceuticals plc
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11.9 Immunomic Therapeutics, Inc.
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Developments
• 11.10 Anergis
  • 11.11.1 Overview
  • 11.11.2 Financial Performance
  • 11.11.3 Product Outlook
  • 11.11.4 Key Developments

12 KEY DEVELOPMENTS

• 12.1 Product Launches/Developments
• 12.2 Mergers and Acquisitions
• 12.3 Business Expansions
• 12.4 Partnerships and Collaborations

13 Appendix

• 13.1 Related Research